Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study

Author： Lenzen Henrike Tsikas Dimitrios Böger Rainer

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.62, Iss.1, 2006-02, pp. : 45-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 2, 2013-01 ,pp. : 180-200

Bentham Science Publishers

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)

By Zoccali Carmine Mallamaci Francesca Tripepi Giovanni

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 131-135

Springer Publishing Company

Access to resources Recommend Favorite

The synthesis and metabolism of asymmetric dimethylarginine (ADMA)

By Leiper James Vallance Patrick

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 33-38

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Asymmetric Dimethylarginine (ADMA) and Leptin in Hypertensive Patients

By Atamer A Ilhan N Kocyigit Y Toprak G Ozbay M Celik Y

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 54-62

Field House Publishing

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis

By Cooke John

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 115-121

Springer Publishing Company

Access to resources Recommend Favorite